Nuvectis Pharma, Inc. (NVCT) 已确认,其研发的抗癌候选药物Nxp900将于2026年美国癌症研究协会(AACR)年会上进行专题展示。这一安排标志着该药物研发进程中的重要一步,届时相关数据与研究成果将面向全球肿瘤学界公布。
Nuvectis Pharma, Inc. (NVCT) 已确认,其研发的抗癌候选药物Nxp900将于2026年美国癌症研究协会(AACR)年会上进行专题展示。这一安排标志着该药物研发进程中的重要一步,届时相关数据与研究成果将面向全球肿瘤学界公布。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.